247 related articles for article (PubMed ID: 29294323)
1. A novel lactoferrin-modified stealth liposome for hepatoma-delivery of triiodothyronine.
Pireddu R; Pibiri M; Valenti D; Sinico C; Fadda AM; Simbula G; Lai F
Int J Pharm; 2018 Feb; 537(1-2):257-267. PubMed ID: 29294323
[TBL] [Abstract][Full Text] [Related]
2. Hepatocellular carcinoma targeting effect of PEGylated liposomes modified with lactoferrin.
Wei M; Xu Y; Zou Q; Tu L; Tang C; Xu T; Deng L; Wu C
Eur J Pharm Sci; 2012 Jun; 46(3):131-41. PubMed ID: 22369856
[TBL] [Abstract][Full Text] [Related]
3. Lactoferrin-modified PEGylated liposomes loaded with doxorubicin for targeting delivery to hepatocellular carcinoma.
Wei M; Guo X; Tu L; Zou Q; Li Q; Tang C; Chen B; Xu Y; Wu C
Int J Nanomedicine; 2015; 10():5123-37. PubMed ID: 26316745
[TBL] [Abstract][Full Text] [Related]
4. [In vitro targeting effect of lactoferrin modified PEGylated liposomes for hepatoma cells].
Wei MY; Zou Q; Wu CB; Xu YH
Yao Xue Xue Bao; 2015 Oct; 50(10):1272-9. PubMed ID: 26837173
[TBL] [Abstract][Full Text] [Related]
5. Design of cholesterol arabinogalactan anchored liposomes for asialoglycoprotein receptor mediated targeting to hepatocellular carcinoma: In silico modeling, in vitro and in vivo evaluation.
Pathak P; Dhawan V; Magarkar A; Danne R; Govindarajan S; Ghosh S; Steiniger F; Chaudhari P; Gopal V; Bunker A; Róg T; Fahr A; Nagarsenker M
Int J Pharm; 2016 Jul; 509(1-2):149-158. PubMed ID: 27231122
[TBL] [Abstract][Full Text] [Related]
6. Fabrication of Imatinib Mesylate-Loaded Lactoferrin-Modified PEGylated Liquid Crystalline Nanoparticles for Mitochondrial-Dependent Apoptosis in Hepatocellular Carcinoma.
Nisha R; Kumar P; Kumar U; Mishra N; Maurya P; Singh S; Singh P; Guleria A; Saha S; Saraf SA
Mol Pharm; 2021 Mar; 18(3):1102-1120. PubMed ID: 33356314
[TBL] [Abstract][Full Text] [Related]
7. PEGylation potentiates hepatoma cell targeted liposome-mediated in vitro gene delivery via the asialoglycoprotein receptor.
Mkhwanazi NK; de Koning CB; van Otterlo WAL; Ariatti M; Singh M
Z Naturforsch C J Biosci; 2017 Jul; 72(7-8):293-301. PubMed ID: 28063265
[TBL] [Abstract][Full Text] [Related]
8. Dual-Targeted Lactoferrin Shell-Oily Core Nanocapsules for Synergistic Targeted/Herbal Therapy of Hepatocellular Carcinoma.
Abdelmoneem MA; Elnaggar MA; Hammady RS; Kamel SM; Helmy MW; Abdulkader MA; Zaky A; Fang JY; Elkhodairy KA; Elzoghby AO
ACS Appl Mater Interfaces; 2019 Jul; 11(30):26731-26744. PubMed ID: 31268657
[TBL] [Abstract][Full Text] [Related]
9. Liposomes for targeting hepatocellular carcinoma: use of conjugated arabinogalactan as targeting ligand.
Shah SM; Goel PN; Jain AS; Pathak PO; Padhye SG; Govindarajan S; Ghosh SS; Chaudhari PR; Gude RP; Gopal V; Nagarsenker MS
Int J Pharm; 2014 Dec; 477(1-2):128-39. PubMed ID: 25311181
[TBL] [Abstract][Full Text] [Related]
10. Effect of a controlled-release drug delivery system made of oleanolic acid formulated into multivesicular liposomes on hepatocellular carcinoma in vitro and in vivo.
Luo Y; Liu Z; Zhang X; Huang J; Yu X; Li J; Xiong D; Sun X; Zhong Z
Int J Nanomedicine; 2016; 11():3111-29. PubMed ID: 27471381
[TBL] [Abstract][Full Text] [Related]
11. Folate receptor-targeted liposomes loaded with a diacid metabolite of norcantharidin enhance antitumor potency for H22 hepatocellular carcinoma both in vitro and in vivo.
Liu MC; Liu L; Wang XR; Shuai WP; Hu Y; Han M; Gao JQ
Int J Nanomedicine; 2016; 11():1395-412. PubMed ID: 27110110
[TBL] [Abstract][Full Text] [Related]
12. Lactosylated liposomes for targeted delivery of doxorubicin to hepatocellular carcinoma.
Zhou X; Zhang M; Yung B; Li H; Zhou C; Lee LJ; Lee RJ
Int J Nanomedicine; 2012; 7():5465-74. PubMed ID: 23093902
[TBL] [Abstract][Full Text] [Related]
13. Transporter occluded-state conformation-induced endocytosis: Amino acid transporter ATB
Luo Q; Gong P; Sun M; Kou L; Ganapathy V; Jing Y; He Z; Sun J
J Control Release; 2016 Dec; 243():370-380. PubMed ID: 27810556
[TBL] [Abstract][Full Text] [Related]
14. Asialoglycoprotein receptor-targeted liposomes loaded with a norcantharimide derivative for hepatocyte-selective targeting.
Liu X; Han M; Xu J; Geng S; Zhang Y; Ye X; Gou J; Yin T; He H; Tang X
Int J Pharm; 2017 Mar; 520(1-2):98-110. PubMed ID: 28167263
[TBL] [Abstract][Full Text] [Related]
15. Thyroid hormone inhibits hepatocellular carcinoma progression via induction of differentiation and metabolic reprogramming.
Kowalik MA; Puliga E; Cabras L; Sulas P; Petrelli A; Perra A; Ledda-Columbano GM; Morandi A; Merlin S; Orrù C; Sanchez-Martin C; Fornari F; Gramantieri L; Parri M; Rasola A; Bellomo SE; Sebastian C; Follenzi A; Giordano S; Columbano A
J Hepatol; 2020 Jun; 72(6):1159-1169. PubMed ID: 31954205
[TBL] [Abstract][Full Text] [Related]
16. Celastrol-Loaded Galactosylated Liposomes Effectively Inhibit AKT/c-Met-Triggered Rapid Hepatocarcinogenesis in Mice.
Chen X; Hu X; Hu J; Qiu Z; Yuan M; Zheng G
Mol Pharm; 2020 Mar; 17(3):738-747. PubMed ID: 31904241
[TBL] [Abstract][Full Text] [Related]
17. RGD conjugated liposome-hollow silica hybrid nanovehicles for targeted and controlled delivery of arsenic trioxide against hepatic carcinoma.
Fei W; Zhang Y; Han S; Tao J; Zheng H; Wei Y; Zhu J; Li F; Wang X
Int J Pharm; 2017 Mar; 519(1-2):250-262. PubMed ID: 28109899
[TBL] [Abstract][Full Text] [Related]
18. Lactoferrin-modified procationic liposomes as a novel drug carrier for brain delivery.
Chen H; Tang L; Qin Y; Yin Y; Tang J; Tang W; Sun X; Zhang Z; Liu J; He Q
Eur J Pharm Sci; 2010 May; 40(2):94-102. PubMed ID: 20298779
[TBL] [Abstract][Full Text] [Related]
19. c(RGDfK) anchored surface manipulated liposome for tumor-targeted tyrosine kinase inhibitor (TKI) delivery to potentiate liver anticancer activity.
Deepak P; Kumar P; Arya DK; Pandey P; Kumar S; Parida BP; Narayan G; Singh S; Rajinikanth PS
Int J Pharm; 2023 Jul; 642():123160. PubMed ID: 37379892
[TBL] [Abstract][Full Text] [Related]
20. Galactose-Modified PH-Sensitive Niosomes for Controlled Release and Hepatocellular Carcinoma Target Delivery of Tanshinone IIA.
Hu X; Zhang J; Deng L; Hu H; Hu J; Zheng G
AAPS PharmSciTech; 2021 Mar; 22(3):96. PubMed ID: 33694067
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
